A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL (ORMD2021)

Fudan University

Status and phase: Active, not recruiting; Phase 1

Conditions: Primary Central Nervous System Lymphoma

Treatments: Drug: Orelabrutinib; Drug: Methotrexate (MTX); Drug: Rituximab; Drug: Dexamethasone

Study type: Interventional

Funder types: Other

Identifiers

NCT05036577

KY2021-726

Details and patient eligibility

About

This is a single arm, single center, open label pilot study of Orelabrutinib combined with Rituximab, high-dose (HD) Methotrexate and Dexamethasone in newly-diagnosed primary central nervous system lymphpoma (PCNSL). The purpose is to evaluate the safety and to find the optimal dose of Orelabrutinib and Methotrexate in this combination treatment for newly-diagnosed PCNSL patients.

Full description

The eligible patients will be treated with Orelabrutinib combined with Rituximab, high-dose Methotrexate and Dexamethasone during induction treatment (6-8 cycles; 21 days/cycle): Rituximab 375 mg/m2, intravenous infusion, d1; HD-MTX 3.5 g/m2 intravenous infusion (3h), d2; Dexamethasone 10-15 mg, iv, d1-4. Orelabrutinib will be given 72h after MTX infusion or until MTX clearance. The study will investigate optimal dose combination of Orelabrutinib and MTX implementing BOIN waterfall design. The starting dose of Orelabrutinib is 150 mg/d and the dose will be escalated to 200 mg/d, throughout the whole cycle. Meanwhile, the starting dose of MTX is 3g/m2 and will be escalated to 5g/m2, throughout induction phase. Dose escalation and movement in dose matrix will be determined by BOIN algorithm. For CR/CRu patients after completion of induction treatment, daily Orelabrutinib will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first). Patients will be evaluated every 2 cycles during induction therapy and every 12 weeks during maintenance therapy.

Enrollment: 15 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• anti-neoplasm systemic treatement naive primary central nervous system lymphoma
• Pathological type is diffuse large B cell lymphoma
• Enough residual sample of tumor after pathological diagnosis
• ECOG =<3
• Life expectancy >3 months
• Adequate organ function and adequate bone marrow reserve
• Must be able to tolerate lumbar puncture and/or have Omaya tube
• Participant or his/her legal agent must be willing to sign a written informed consent document.

Exclusion criteria

• Lymphoma invading outside CNS
• Lymphoma only existed in vitreo-retina
• Severe or uncontrolled cardiovascular disease
• Active hemorrhage within 2 months prior screening
• Cerebral ischemic stroke or bleeding within 6 months prior screening
• Organ transplantation or allogeneic hematopoietic stem cell transplantation history
• Other surgery history within 6 weeks prior screening
• Anti-tumor herbal medicine treatment within 4 weeks prior screening
• Activated or uncontrolled hepatitis virus B infection (HBsAg positive with/or HBc Ab positive and HBV-DNA titration positive), hepatitis virus C antibody positive, HIV positive.
• Uncontrolled active systemic fungal, bacterial, virus or other microbe infection, or intravenous injection of antibiotics needed
• Accepted live vaccine or immunization within 4 weeks prior eligibility
• Continuously taking drugs with medium / strong inhibition or induction of cytochrome P450 CYP3A is needed
• Allergy to orelabrutinib or the subsidiary (or supplementary) material (Hydroxypropyl methylcellulose acetate succinate, mannitol, cross-linked sodium carboxymethylcellulose, hydroxypropyl cellulose, silica and magnesium stearate)
• Obvious gastro-bowel disease which may influence the intaking, transportation or absorption of the drug, or total gastrectomy
• Past or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, or drug-related pneumonia, with severe impairment of pulmonary function
• Chronic liver damage, severe fatty liver or alcoholic liver disease
• Intention to undergo autologous stem cell transplantation
• Pregnant or breeding women, or women of childbearing age who are unwilling to take contraceptive measures during the whole study period and within 180 days after the last administration of the study drug; non surgically sterilized men who are unwilling to take contraceptive measures during the whole study period and within 180 days of the last administration of the study drug.
• Potentially life-threatening situation, or severe organ dysfunction, or situations the researchers believe not suitable for the trial
• Any mental or cognitive impairment which may limit the understanding and implementation of informed consent or the compliance with the study.
• previously exposed with WBRT

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

ORMD (Orelabrutinib, Rituximab, Methotrexate and Dexamethasone)

Experimental group

Description:

Patients were treated for 6-8 cycles of induction therapy with 21 days per cycle, receiving rituximab (375mg/m2 on day 1), dexamethasone (10-15mg on d1-d4), MTX (d2, 3.5g/m2 or 5g/m2), and orelabrutinib (once daily, after MTX clearance, 150mg/d, or 200mg/d), followed by orelabrutinib maintenance up to one year among CR/CRu patients or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first). The primary objective was to determine the maximum tolerated dose (MTD) of the combination of orelabrutinib and MTX with R and D and investigate the safety and tolerability of this regimen using Bayesian Optimal Interval (BOIN) waterfall design to determine rule of dose escalation and movement among dose combination matrix to identify MTD contour.

Treatment:

Drug: Dexamethasone

Drug: Rituximab

Drug: Methotrexate (MTX)

Drug: Orelabrutinib